Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells

Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas

(2011) Naoki Mori et al.   BIOCHEMICAL PHARMACOLOGY

The Aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe

(2011) Yungan Tao et al.   CELL CYCLE

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

(2011) Kosuke Tsuboi et al.   LEUKEMIA RESEARCH

Enhanced Radiosensitivity of Androgen-Resistant Prostate Cancer: AZD1152-Mediated Aurora Kinase B Inhibition

(2011) Kenneth J Niermann et al.   RADIATION RESEARCH

New Trends in the Standard of Care for Initial Therapy of Acute Myeloid Leukemia

(2011) H. F. Fernandez   Hematology-American Society of Hematology Education Program

Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

(2010) M. Payton et al.   CANCER RESEARCH

AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947

(2010) S. Libertini et al.   ENDOCRINE-RELATED CANCER

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer

(2010) Christopher P Gully et al.   Molecular Cancer

The FLT3 Internal Tandem Duplication Mutation Is a Secondary Target of the Aurora B Kinase Inhibitor AZD1152-HQPA in Acute Myelogenous Leukemia Cells

(2010) M. Grundy et al.   MOLECULAR CANCER THERAPEUTICS

Mitotic drivers—inhibitors of the Aurora B Kinase

(2009) Nicholas Keen et al.   CANCER AND METASTASIS REVIEWS

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo

(2009) A. Oke et al.   CANCER RESEARCH

The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo

(2009) J. S. Nair et al.   CLINICAL CANCER RESEARCH

The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model

(2009) E. C. VanderPorten et al.   MOLECULAR CANCER THERAPEUTICS

New approaches in acute myeloid leukemia

(2008) William Blum et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma

(2008) Robert P. Evans et al.   BRITISH JOURNAL OF HAEMATOLOGY

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

(2008) E. Walsby et al.   HAEMATOLOGICA